Open AccessAbstract CT122: Phase I dose-escalation study of prostate-specific membrane antigen (PSMA)-targeted alpha emitter 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC)
Author(s) -
Scott T. Tagawa,
Joseph R. Osborne,
Charlene Thomas,
E. Rodriguez Fernandez,
Muhammad Junaid Niaz,
Shankar Vallabhajosula,
Panagiotis J. Vlachostergios,
Ana M. Molina,
Cora N. Sternberg,
Sharon Singh,
Amie Patel,
Angela Tan,
John W. Babich,
David M. Nanus,
Karla V. Ballman,
Neil H. Bander
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct122
Subject(s) - medicine , prostate cancer , toxicity , taxane , enzalutamide , oncology , radioimmunotherapy , cancer , urology , antibody , monoclonal antibody , breast cancer , immunology , androgen receptor